Synthetic lethal approaches to breast cancer therapy (original) (raw)

• Beslija, S. et al. Third consensus on medical treatment of metastatic breast cancer. Ann. Oncol. 20, 1771–1785 (2009).
  Article CAS PubMed Google Scholar
• Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
  Article CAS PubMed Google Scholar
• Fisher, B. et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J. Natl Cancer Inst. Monogr. 2001, 62–66 (2001).
  Article Google Scholar
• Collins, I. & Workman, P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2, 689–700 (2006).
  Article CAS PubMed Google Scholar
• Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191–196 (2010).
  Article CAS PubMed Google Scholar
• Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893–898 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Weinstein, I. B. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 297, 63–64 (2002).
  Article CAS PubMed Google Scholar
• Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077–3080 (2008).
  Article CAS PubMed Google Scholar
• Lord, C. J. & Ashworth, A. Biology-driven cancer drug development: back to the future. BMC Biol. 8, 38 (2010).
  Article PubMed PubMed Central Google Scholar
• Cleator, S. J., Ahamed, E., Coombes, R. C. & Palmieri, C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin. Breast Cancer 9 (Suppl. 1), S6–S17 (2009).
  Article CAS PubMed Google Scholar
• Love, R. R. & Philips, J. Oophorectomy for breast cancer: history revisited. J. Natl Cancer Inst. 94, 1433–1434 (2002).
  Article PubMed Google Scholar
• Berger, M. S. et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48, 1238–1243 (1988).
  CAS PubMed Google Scholar
• Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of _HER2_-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
  Article CAS PubMed Google Scholar
• Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648 (1999).
  Article CAS PubMed Google Scholar
• Harries, M. & Smith, I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer 9, 75–85 (2002).
  Article CAS PubMed Google Scholar
• Brandes, A. A., Franceschi, E., Tosoni, A. & Degli Esposti, R. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Rev. Anticancer Ther. 10, 179–184 (2010).
  Article CAS PubMed Google Scholar
• Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. & Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 93, 1852–1857 (2001).
  Article CAS PubMed Google Scholar
• Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214–3231 (2007).
  Article CAS PubMed Google Scholar
• Konopka, J. B., Watanabe, S. M. & Witte, O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37, 1035–1042 (1984).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002).
  Article CAS PubMed Google Scholar
• Chapman, P. et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 [abstract]. Eur. J. Cancer Suppl. 7, 6BA (2009).
  Google Scholar
• Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Roa, B. B., Boyd, A. A., Volcik, K. & Richards, C. S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet. 14, 185–187 (1996).
  Article CAS PubMed Google Scholar
• Oddoux, C. et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat. Genet. 14, 188–190 (1996).
  CAS PubMed Google Scholar
• Dobzhansky, T. Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31, 269–290 (1946).
  CAS PubMed PubMed Central Google Scholar
• Lucchesi, J. C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 59, 37–44 (1968).
  CAS PubMed PubMed Central Google Scholar
• Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).
  Article CAS PubMed Google Scholar
• Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689–698 (2005).
  Article CAS PubMed Google Scholar
• Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
  Article CAS PubMed Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
  Article CAS PubMed Google Scholar
• Amé, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882–893 (2004).
  Article PubMed Google Scholar
• Tutt, A. N. et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139–148 (2005).
  Article CAS PubMed Google Scholar
• Symington, L. S. Focus on recombinational DNA repair. EMBO Rep. 6, 512–517 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Arnaudeau, C., Lundin, C. & Helleday, T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol. 307, 1235–1245 (2001).
  Article CAS PubMed Google Scholar
• McCabe, N. et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency. Cancer Biol. Ther. 4, 934–936 (2005).
  Article CAS PubMed Google Scholar
• Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).
  Article CAS PubMed Google Scholar
• Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
  Article CAS PubMed Google Scholar
• Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512–2519 (2010).
  Article CAS PubMed Google Scholar
• Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).
  Article CAS PubMed Google Scholar
• Tutt, A. et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer [abstract]. J. Clin. Oncol. 27, CRA501 (2009).
  Article Google Scholar
• Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).
  Article CAS PubMed Google Scholar
• Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814–819 (2004).
  CAS PubMed Google Scholar
• Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349, 1505–1510 (1997).
• Bergamaschi, A. et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45, 1033–1040 (2006).
  Article CAS PubMed Google Scholar
• Horlings, H. M. et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin. Cancer Res. 16, 651–663 (2010).
  Article CAS PubMed Google Scholar
• Turner, N. C. & Reis-Filho, J. S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25, 5846–5853 (2006).
  Article CAS PubMed Google Scholar
• O'Shaughnessy, J. et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: results of a randomized phase II trial [abstract]. J. Clin. Oncol. 27, 3 (2009).
  Article Google Scholar
• O'Shaughnessy, J. O. et al. Updated results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer [abstract]. San Antonio Breast Cancer Symposium Annual Meeting, 3122 (2009).
• Chen, G. & Pan, Q. C. Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. Cancer Chemother. Pharmacol. 22, 303–307 (1988).
  Article PubMed Google Scholar
• Pan, Q. C. & Guo, H. Y. The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide. J. Antibiot. (Tokyo) 42, 1860–1868 (1989).
  Article CAS Google Scholar
• Zaremba, T. & Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7, 515–523 (2007).
  Article CAS PubMed Google Scholar
• Heinemann, V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin. Breast Cancer 3 (Suppl. 1), 24–29 (2002).
  Article PubMed Google Scholar
• Sirohi, B. et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 19, 1847–1852 (2008).
  Article CAS PubMed Google Scholar
• Gelmon, K. A. et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. J. Clin. Oncol. 28, 3002 (2010).
  Article Google Scholar
• Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403–414 (2008).
  Article CAS PubMed Google Scholar
• Yin, Y. & Shen, W. H. PTEN: a new guardian of the genome. Oncogene 27, 5443–5453 (2008).
  Article CAS PubMed Google Scholar
• Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Shen, W. H. et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157–170 (2007).
  Article CAS PubMed Google Scholar
• Gupta, A. et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8, 2198–2210 (2009).
  Article CAS PubMed Google Scholar
• Graeser, M. K. et al. A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-10-1027.
  Article CAS PubMed PubMed Central Google Scholar
• Mukhopadhyay, A. et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344–2351 (2010).
  Article CAS PubMed Google Scholar
• Asakawa, H. et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res. 12, R17 (2010).
  Article PubMed PubMed Central Google Scholar
• Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Onc. 28, 3555–3561 (2010).
  Article CAS Google Scholar
• Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in _BRCA2_-mutated ovarian carcinoma. Cancer Res. 69, 6381–6386 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in _BRCA2_-mutated cancers. Nature 451, 1116–1120 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Swisher, E. M. et al. Secondary BRCA1 mutations in _BRCA1_-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581–2586 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gottipati, P. et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 70, 5389–5398 (2010).
  Article CAS PubMed Google Scholar
• Natrajan, R. et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 15, 2711–2722 (2009).
  Article CAS PubMed Google Scholar
• Hynes, N. E. & Stoelzle, T. Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res. 11, 210 (2009).
  Article PubMed PubMed Central Google Scholar
• Wang, Y. et al. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5, 501–512 (2004).
  Article CAS PubMed Google Scholar
• Di Leva, G. & Croce, C. M. Roles of small RNAs in tumor formation. Trends Mol. Med. 16, 257–267 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Weng, L. P. et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res. 59, 5808–5814 (1999).
  CAS PubMed Google Scholar
• Baldwin, A. et al. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc. Natl Acad. Sci. USA 107, 12463–12468 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ruzankina, Y. et al. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat. Genet. 41, 1144–1149 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175–189 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).
  Article CAS PubMed Google Scholar
• Williamson, C. T. et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 9, 347–357 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dong, Y., Li, A., Wang, J., Weber, J. D. & Michel, L. S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 70, 5465–5474 (2010).
  Article CAS PubMed Google Scholar
• Bauzon, F. & Zhu, L. Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. Cell Cycle 9, 2118–2123 (2010).
  Article CAS PubMed Google Scholar
• Molenaar, J. J. et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc. Natl Acad. Sci. USA 106, 12968–12973 (2009).
  Article CAS PubMed PubMed Central Google Scholar